G
Glympse Bio
Transforming disease detection and monitoring drug response
About Glympse Bio
Glympse Bio is a pioneering biotechnology company focused on transforming the way diseases are detected, tracked, and treated. The company specializes in developing noninvasive biosensors that measure real-time biological signals, translating them into clinically actionable results. These biosensors are designed to monitor disease progression by directly querying biological activity, offering a novel approach to understanding complex diseases such as cancer, fibrosis, inflammation, and infections.
Read full description
Operating in the healthcare and biotechnology markets, Glympse Bio serves pharmaceutical companies, healthcare providers, and researchers. The company's business model revolves around the development and commercialization of its proprietary biosensors, which are tailored for specific protease-mediated diseases. Revenue is generated through partnerships, licensing agreements, and direct sales of their biosensor technology.
By leveraging advances in engineering, medicine, biotechnology, and machine learning, Glympse Bio aims to accelerate drug development and improve patient outcomes. The company blends the best practices from drug device development, regulatory pathways, and a data-rich biology engine to offer a comprehensive solution for disease monitoring and treatment.
At a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 69.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Nanotech
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Glympse Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2023 | $0 | — | Sunbird Bio | ↗ |
| LATE VCOther financing | Dec 2021 | $18M | $72M | Undisclosed | — |
Growth signals
Latest recorded traffic for Glympse Bio is 290 monthly website visits, down 23.7% over the last three months. Glympse Bio's team declined 44.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A11 investors entered at this stage
Polaris Partners
ARCH Venture Partners
CRV
Section 32
Temasek
New Leaf Venture Partners
GreatPoint Ventures- WVWaterman Ventures
DNS Capital
Gilead Sciences
Catalio Capital Management
Other known investors2 additional known investors
Massachusetts Institute of Technology
Sunbird Bio
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Glympse Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Glympse Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.